Helminthostachys zeylanica(L.)Hook

Small molecule

Helminthostachys zeylanica(L.)Hook is one of 13 small molecule programs targeting Ankle Fracture. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ankle FractureActive, not recruiting

Ankle FracturePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Ankle Fracture

#DrugCompanyPhaseTrials

Aleve

Alnylam Pharmaceuticals

Approved

1 2

Naropin

FFresenius Kabi Oncology Ltd.

Approved

3 3

Oxycontin

PProtega

Approved

1 4

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 5

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

1 6

Tylenol

Marcaine

1 8

Forsteo

Novartis

Approved

1 9

Bayer Aspirin

Bayer

Phase 1

1 10

Advil

KKenvue Brands

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ankle Fracture1 trial

The Therapeutic Effect of Dau-Di-Wu-Gong in Patient With Ankle Fracture

Completed·—·Phase 1/2·NCT03805347·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Helminthostachys zeylanica(L.)Hook. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Helminthostachys zeylanica(L.)Hook compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Helminthostachys zeylanica(L.)Hook. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changhua Christian Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: CChanghua Christian Hospital

Helminthostachys zeylanica(L.)Hook

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ankle Fracture1 trial

References

Drug Info

Quick Facts

Related News